Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
What made us buy IEX@193, Tata Power@56, Titan@330, Divis@629, Persistent@700.
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Sharon Bio-Medicine Ltd Stock Analysis

Small Cap
Evaluated by 741 users | BSE: 532908 | NSE: SHARONBIO |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Jun'06Jun'07Jun'08Jun'09Jun'10Jun'11Jun'12Jun'13Jun'14Jun'15Mar'16TTM
Return on Capital Employed 32.54%23.11%14.96%8.78%8.4%9.93%10.56%10.45%11.31%-10.61%-24.99%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 89.11713354204976067851,0601,314834338182
Y-o-Y Gr. Rt.-91.9%95.7%25.5%18.3%22.1%29.5%35%24%-36.5%-59.5%-
Adjusted EPS (Rs.) 1.071.752.581.841.932.963.945.016.59-14.48-27.9433.26
Y-o-Y Gr. Rt.-63.6%47.4%-28.7%4.9%53.4%33.1%27.2%31.5%-319.7%NA-
Book Value per Share (Rs.) 2.294.287.639.2510.8613.613.0517.8924.067.98-22.9-54.30
Adjusted Net Profit 10.717.927.219.420.331.341.652.969.6-172-33219
Net Op. Cash Flow (Rs. Cr.) -5-14.2-40.5-50.1-28.1-36-53-70.2-69.5-81.9-37.6-
Debt to Cash Flow from Ops -3.3-4.62-5.3-5.24-12.19-9.55-9.58-9.17-10.44-10.07-29.65-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Sharon Bio-Medicine Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 7.9%-11%-31.7%-59.5%
Adjusted EPS -236.1%-256.7%-277.3%NA
Book Value per Share -220.5-211-208.6-387
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Jun'06Jun'07Jun'08Jun'09Jun'10Jun'11Jun'12Jun'13Jun'14Jun'15Mar'16TTM
Return on Equity (%) 47.9240.6637.4419.9517.7619.4521.2724.223.68-74.56786.18-86.17
Operating Profit Margin (%) 15.5815.211.689.5510.5111.6612.1411.3711.95-4.12-52.8114.53
Net Profit Margin (%) 12.0410.458.134.634.15.165.34.995.3-20.65-98.3410.51
Debt to Equity 0.711.52.662.692.992.393.683.412.868.68-4.09-
Working Capital Days 103126131168190198203198202322761300
Cash Conversion Cycle 758598141164170167165169272657-
Loading price chart...
Entity Percentage Holding
Institutions 0.02%
Non-Institutions 99.98%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Data is not available for this company.

Sharon Bio-Medicine, established in 1989, is into manufacturing and supply of Active Pharmaceutical Ingredients (APIs).

The company has established its name as a reliable supplier of intermediates. In international markets, the company serves Latin America, Middle East, South East Asia and SAARC countries. With the setting up of new facilities Sharon has geared up to enter other markets such as Europe, Japan, Australia and USA in the next two years.

With setting and successful

Sharon Bio-Medicine, established in 1989, is into manufacturing and supply of Active Pharmaceutical Ingredients (APIs).

The company has established its name as a reliable supplier of intermediates. In international markets, the company serves Latin America, Middle East, South East Asia and SAARC countries. With the setting up of new facilities Sharon has geared up to enter other markets such as Europe, Japan, Australia and USA in the next two years.

With setting and successful commercialisation of the solid dosage formulation facility at Dehradun, its formulations are now being marketed in Africa, Latin America and other markets.

The company’s research team constantly seeks development of non-infringing routes for APIs in therapeutic segments like cardiovascular diseases and anti-ulcerants.

It also offers contract manufacturing for finished dosage forms; viz. tablets, capsules and injectables. Sharon has identified niche areas of oncology for export markets.

Products

  • APIs and Pellets
  • Intermediates
  • Formulations

Milestones

  • 1995 - The current management took over and started manufacturing of pharma intermediates
  • 1997 - The company started manufacturing APIs and launched its first drug -- trimetazidine di hydrochloride -- a cardiovascular drug.
  • 2000 - The company came out with public offering of 25% stake. The issue was oversubscribed by 3.85 times. It set up a R&D block to carry out process synthesis for APIs and intermediates.
  • 2005 - The company received ISO 9001-2000 accreditation by BVQI-UKAS and BVQI-ANAB
  • 2006 - It started construction of a state-of-the-art formulation unit for oral solid dosages at Dehradun, New Delhi with an estimated cost of $8 million.
  • 2007 - The company commissioned its formulation plant. It also started supplying formulations to reputed pharmaceutical companies in India on contract manufacturing basis.
  • 2009 - The company set up and operationalised a new business division by name SA-Ford dedicated to toxicology studies. It also set up and operationalised a state-of-the-art API plant at Taloja, near Mumbai, which enables it to offer a wide variety of services to its customers.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback